de Wit R, Bakker P J, Danner S A, Goudsmit J, Veenhof K H
Division of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands.
Int J STD AIDS. 1990 Jul;1(4):256-8. doi: 10.1177/095646249000100405.
Anti-interferon (IFN)-alpha antibodies were determined in the serum of 28 patients treated with high-dose human recombinant IFN-alpha-2a for AIDS-associated Kaposi's sarcoma. After a median treatment duration of 3 months, 3 patients developed anti-IFN-alpha antibodies, of whom 2 showed a long lasting tumour response despite the development of these antibodies. None of 3 patients with tumour progression after an initial treatment response had developed IFN-alpha neutralizing antibodies. In conclusion, a low incidence of anti-IFN-alpha antibodies during treatment with high dose IFN-alpha was found, but the appearance had no detrimental effect on the duration of tumour responses in a small number of patients.
在28例接受高剂量人重组干扰素α-2a治疗艾滋病相关卡波西肉瘤的患者血清中检测抗干扰素（IFN）-α抗体。中位治疗持续时间为3个月后，3例患者产生了抗IFN-α抗体，其中2例尽管产生了这些抗体，但仍表现出持久的肿瘤反应。在最初治疗有反应后出现肿瘤进展的3例患者中，无一例产生IFN-α中和抗体。总之，发现高剂量IFN-α治疗期间抗IFN-α抗体的发生率较低，但在少数患者中，抗体的出现对肿瘤反应持续时间没有不利影响。
